Vaxil Bio Ltd (VXL) - Total Assets
Based on the latest financial reports, Vaxil Bio Ltd (VXL) holds total assets worth CA$675.00K CAD (≈ $488.28K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Vaxil Bio Ltd (VXL) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Vaxil Bio Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Vaxil Bio Ltd's total assets have evolved over time, based on quarterly financial data. See VXL net asset value for net asset value and shareholders' equity analysis.
Vaxil Bio Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Vaxil Bio Ltd's total assets of CA$675.00K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 61.1% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Vaxil Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Vaxil Bio Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxil Bio Ltd's current assets represent 100.0% of total assets in 2024, an increase from 61.2% in 2009.
- Cash Position: Cash and equivalents constituted 61.1% of total assets in 2024, up from 48.1% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vaxil Bio Ltd Competitors by Total Assets
Key competitors of Vaxil Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Vaxil Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 75.38 | 10.00 | 1.91 |
| Quick Ratio | 75.38 | 10.00 | 1.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$595.00K | CA$738.00K | CA$777.00K |
Vaxil Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Vaxil Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -24.9% |
| Total Assets | CA$733.00K |
| Market Capitalization | $307.17K USD |
Valuation Analysis
Below Book Valuation: The market values Vaxil Bio Ltd's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vaxil Bio Ltd's assets decreased by 24.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vaxil Bio Ltd (2009–2024)
The table below shows the annual total assets of Vaxil Bio Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$733.00K ≈ $530.24K |
-24.90% |
| 2023-12-31 | CA$976.00K ≈ $706.02K |
-36.66% |
| 2022-12-31 | CA$1.54 Million ≈ $1.11 Million |
-32.56% |
| 2021-12-31 | CA$2.29 Million ≈ $1.65 Million |
+37.57% |
| 2020-12-31 | CA$1.66 Million ≈ $1.20 Million |
+710.24% |
| 2019-12-31 | CA$205.00K ≈ $148.29K |
-76.97% |
| 2018-12-31 | CA$890.00K ≈ $643.81K |
+187.10% |
| 2017-12-31 | CA$310.00K ≈ $224.25K |
-74.53% |
| 2016-12-31 | CA$1.22 Million ≈ $880.36K |
+319.66% |
| 2015-12-31 | CA$290.00K ≈ $209.78K |
+150.37% |
| 2014-12-31 | CA$115.83K ≈ $83.79K |
-54.21% |
| 2013-12-31 | CA$252.93K ≈ $182.96K |
-6.72% |
| 2012-12-31 | CA$271.16K ≈ $196.16K |
-25.35% |
| 2011-12-31 | CA$363.26K ≈ $262.78K |
-49.56% |
| 2010-12-31 | CA$720.23K ≈ $521.00K |
+32.17% |
| 2009-12-31 | CA$544.94K ≈ $394.20K |
-- |
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.